Skip to search formSkip to main contentSkip to account menu

Tysabri

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Abstract The objective of the study was to obtain information on the toxicity of biosimilar natalizumab (PB006) in comparison to… 
2019
2019
Background There is a significant UK variation in the DMT sequencing strategies for high PML risk patients on Tysabri. In Greater… 
2018
2018
Introduction We aimed to report a single patient seen at a tertiary neurology centre with a rarely described phenomenon of… 
2017
2014
2014
Entyvio (vedolizumab), Takeda’s drug for inflammatory bowel disease (IBD), is in line to become the first integrin inhibitor to… 
Review
2010
Review
2010
1135 has shown side effects that include a slowed heart rate, macular edema and breathing and liver problems. Although these may… 
Review
2009
Review
2009
Therapeutic monoclonal antibodies are potent new tools for a molecular targeted approach to modify the course of multiple… 
2008
2008
La Agencia Espanola de Medicamentos y Productos Sanitarios (AEMPS) ha recibido nueva informacion de seguridad concerniente al… 
2005
2005
Although the financial implications of Elan's and Biogen Idec's shock withdrawal from the market of the highly promising multiple…